Rosetta Genomics Ltd
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LU… Read more
Rosetta Genomics Ltd (ROSGQ) - Total Liabilities
Latest total liabilities as of June 2017: $5.11 Million USD
Based on the latest financial reports, Rosetta Genomics Ltd (ROSGQ) has total liabilities worth $5.11 Million USD as of June 2017.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rosetta Genomics Ltd - Total Liabilities Trend (2004–2016)
This chart illustrates how Rosetta Genomics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rosetta Genomics Ltd Competitors by Total Liabilities
The table below lists competitors of Rosetta Genomics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spod Lithium Corp.
OTCQB:SPODF
|
USA | $676.03K |
|
EZTD Inc
PINK:EZTD
|
USA | $17.66 Million |
|
STI Education Systems Holdings Inc
PSE:STI
|
Philippines | ₱6.57 Billion |
Liability Composition Analysis (2004–2016)
This chart breaks down Rosetta Genomics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.82 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rosetta Genomics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rosetta Genomics Ltd (2004–2016)
The table below shows the annual total liabilities of Rosetta Genomics Ltd from 2004 to 2016.
| Year | Total Liabilities | Change |
|---|---|---|
| 2016-12-31 | $7.54 Million | +169.14% |
| 2015-12-31 | $2.80 Million | +26.66% |
| 2014-12-31 | $2.21 Million | -1.51% |
| 2013-12-31 | $2.25 Million | +37.85% |
| 2012-12-31 | $1.63 Million | -32.08% |
| 2011-12-31 | $2.40 Million | -59.48% |
| 2010-12-31 | $5.92 Million | +0.37% |
| 2009-12-31 | $5.90 Million | +41.58% |
| 2008-12-31 | $4.17 Million | +71.31% |
| 2007-12-31 | $2.43 Million | +13.48% |
| 2006-12-31 | $2.14 Million | -72.13% |
| 2005-12-31 | $7.69 Million | +873.67% |
| 2004-12-31 | $790.00K | -- |